Back to top
more

Johnson & Johnson (JNJ)

(Real Time Quote from BATS)

$155.75 USD

155.75
2,467,669

+0.28 (0.18%)

Updated Nov 11, 2024 12:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Wall Street banks and other household brands report earnings results.

by Zacks Equity Research

Wall Street banks and other household brands report earnings results.

    J&J (JNJ) Beats on Q2 Earnings, Lags Sales, Ups 2017 View

    by Zacks Equity Research

    Johnson & Johnson (JNJ) reported mixed second-quarter 2017 results. While earnings beat expectations, sales missed the same.

      Novartis Tops Q2 Earnings, Sandoz Faces Pricing Pressure

      by Zacks Equity Research

      Novartis AG (NVS) reported second-quarter 2017 core earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.16 but the recorded figure was a penny lower than the year-ago figure of $1.23.

        Mark Vickery headshot

        Q2 Earnings Reports Hit the Tape: GS, BAC, JNJ, LMT & UNH

        by Mark Vickery

        Goldman Sachs (GS) beat estimates on both top and bottom lines, but shares are selling off following this earnings report on drastically lower fixed income revenues.

          Kinjel Shah headshot

          J&J (JNJ) Beats on Q2 Earnings, Ups 2017 EPS & Sales View

          by Kinjel Shah

          Johnson & Johnson (JNJ) reported mixed second-quarter 2017 results, with earnings beating expectations while sales slightly missing the same.

            Tracey Ryniec headshot

            Earnings All Stars with Perfect Charts

            by Tracey Ryniec

            Don't just settle for good earnings surprise records when you can have great with these 5 companies who report this week.

              Arpita Dutt headshot

              4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings

              by Arpita Dutt

              Here is a look at four drug stocks including Anika (ANIK) with a Sell Rank and negative earnings ESP that should be avoided ahead of earnings.

                J&J (JNJ) Gets FDA Nod for Psoriasis Drug -- Guselkumab

                by Zacks Equity Research

                Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate-to-severe plaque psoriasis. The drug will be marketed by the trade name of Tremfya.

                  Abbott Partners Bigfoot Biomedical to Expand in Diabetics

                  by Zacks Equity Research

                  Illinois-based global medical device company Abbott Laboratories (ABT) partnered with Bigfoot Biomedical to solidify its footprint in the rapidly growing diabetes therapeutics market.

                    Amgen's Myeloma Drug Improves Overall Survival in Phase III

                    by Zacks Equity Research

                    Biotech major, Amgen, Inc. (AMGN) announced final data from the phase III ASPIRE study, which showed that a combination regimen of its drug, Kyprolis, significantly improved overall survival (OS) in patients with relapsed multiple myeloma.

                      J&J (JNJ) to Commence Pharma Q2 Earnings Season: What's Up?

                      by Zacks Equity Research

                      Johnson & Johnson (JNJ), a healthcare bellwether, will report second-quarter 2017 results on Jul 18.

                        Madeleine Johnson headshot

                        Here's Why Arena Pharmaceuticals (ARNA) Stock is Skyrocketing Today

                        by Madeleine Johnson

                        On Tuesday, shares of biopharmaceutical company Arena Pharmaceuticals (ARNA) are skyrocketing, up about 41% to $26.10 per share in afternoon trading after it reported positive mid-stage trial results for one of its drugs.

                          Arena's Ralinepag Positive in Phase II PAH Study, Shares Up

                          by Zacks Equity Research

                          Arena Pharmaceuticals, Inc. (ARNA) shares surged 41.3% in after-market trading on Monday after its phase II study evaluating its key pipeline candidate, ralinepag, in pulmonary arterial hypertension, met the primary endpoint.

                            Novartis' Cosentyx Superior to Stelara in Psoriasis Study

                            by Zacks Equity Research

                            Novartis' (NVS) psoriasis drug Cosentyx got a label update from the Committee for Medicinal Products for Human Use (CHMP) in the EU,

                              Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical

                              by Zacks Equity Research

                              Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical

                                Microsoft Unveils Software to Enhance Employee Productivity

                                by Zacks Equity Research

                                Microsoft Corp. (MSFT) recently launched its long awaited employee performance analysis software called Workplace Analytics.

                                  Geron Stock Up Almost 40% So Far This Year After '16 Decline

                                  by Zacks Equity Research

                                  Geron Corporation's (GERN) shares have risen 38.7% this year so far, outperforming the Zacks classified Medical - Biomedical and Genetics industry, which rose 5.6%. This comes after a decline of more than 57% in 2016.

                                    Cardiome's Partner SteadyMed Submits NDA for PAH Injection

                                    by Zacks Equity Research

                                    Cardiome Pharma Corp. (CRME) announced that its partner SteadyMed Ltd. (STDY) has submitted a new drug application (NDA) to the FDA for its lead candidate, Trevyent (treprostinil injection), for treatment of pulmonary arterial hypertension (PAH).

                                      Alkermes Presents Phase III Data on Schizophrenia Candidate

                                      by Zacks Equity Research

                                      Alkermes plc (ALKS) announced positive preliminary top-line results from a phase III study, ENLIGHTEN-1, evaluating its schizophrenia candidate, ALKS 3831.

                                        Arena Ends Study on Extended Release Formulation of PAH Drug

                                        by Zacks Equity Research

                                        Arena Pharmaceuticals, Inc. (ARNA), announced that it has completed an early-stage study comparing the once-daily, extended release (XR) formulation of its experimental pulmonary arterial hypertension (PAH) candidate, ralinepag, with its twice-daily immediate release (IR) formulation.

                                          Sheraz Mian headshot

                                          Top Research Reports for JNJ, AT&T & Lockheed Martin

                                          by Sheraz Mian

                                          Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), AT&T (T), and Lockheed Martin (LMT).

                                            Aduro Starts Phase II Combo Study with CRS-207 & Keytruda

                                            by Zacks Equity Research

                                            Aduro Biotech, Inc. (ADRO) has announced initiation of a phase II study to evaluate a combination therapy of its lead candidate, CRS-207, in combination with Keytruda, for treatment of patients with pleural mesothelioma (MPM).

                                              Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

                                              by Zacks Equity Research

                                              Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

                                                Nilanjan Choudhury headshot

                                                How to Interpret Big Oil's Support for a Carbon Tax

                                                by Nilanjan Choudhury

                                                Surprisingly, some of the biggest energy companies have joined the call advocating for a progressively rising carbon tax.

                                                  Arpita Dutt headshot

                                                  Better Days Ahead for the Pharma Sector?

                                                  by Arpita Dutt

                                                  Sales, R&D, strong results, and a higher number of FDA approvals.